Is the time between first diagnosis of paroxysmal atrial fibrillation and cryoballoon ablation a predictor of efficacy?

Maurizio Lunati, Giuseppe Arena, Saverio Iacopino, Roberto Verlato, Claudio Tondo, Antonio Curnis, Stefano Porcellini, Luigi Sciarra, Giulio Molon, Gaetano Senatore, Loira Leoni, Giovanni Battista Perego, Werner Rauhe, Patrizia Pepi, Maurizio Landolina

Research output: Contribution to journalArticle

Abstract

Aims Cryoablation is an indicated therapy for the treatment of recurrent atrial fibrillation through pulmonary vein isolation; however, the optimal time between first diagnosis of atrial fibrillation and cryoablation is still unknown. We aimed to assess the clinical efficacy and safety of early versus later treatment of patients with paroxysmal atrial fibrillation by cryoablation. Methods Five hundred and ten patients underwent atrial fibrillation cryoablation and were prospectively followed for at least 6 months in 43 Italian cardiology centers. The population was divided into two groups according to the time since the first diagnosis of atrial fibrillation until the index cryoablation procedure. An early-treatment group had an elapsed time of 15 months or less from atrial fibrillation diagnosis until cryoablation, and the late-treatment group had an elapsed time of greater than 15 months. During the evaluation, clinical efficacy was defined as atrial fibrillation recurrence outside a landmark 90-day blanking period, and safety was defined as the reporting of all procedure-related complications. Results In the total cohort, cryoablation was performed after a median of 36 months from the point of the patient diagnosis with drug refractory symptomatic recurrent atrial fibrillation. The early-treatment group was composed of 130 (25%) patients, whereas the late-treatment group had 380 (75%) patients. Both cohorts had similar baseline clinical characteristics. Of 510 patients, 22 had a complication related to the procedure with no difference between the two groups. Multivariable analysis showed that the risk of atrial fibrillation recurrence was significantly higher in the late-treatment group (hazard ratio: 1.77; 95% confidence interval 1.00-3.13) Conclusion In our multicenter observational examination, cryoablation was well tolerated and effective in the treatment of patients with drug refractory symptomatic paroxysmal atrial fibrillation. Reducing the time between diagnosis and ablation brought about a treatment that had a lower risk of atrial fibrillation recurrence with no change in safety. (Italian ClinicalService Project: NCT01007474).
Original languageEnglish
Pages (from-to)446-452
Number of pages7
JournalJournal of Cardiovascular Medicine
Volume19
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

    Fingerprint

Keywords

  • atrial fibrillation recurrences
  • cryoablation
  • early ablation
  • outcomes
  • paroxysmal atrial fibrillation

Cite this

Lunati, M., Arena, G., Iacopino, S., Verlato, R., Tondo, C., Curnis, A., Porcellini, S., Sciarra, L., Molon, G., Senatore, G., Leoni, L., Perego, G. B., Rauhe, W., Pepi, P., & Landolina, M. (2018). Is the time between first diagnosis of paroxysmal atrial fibrillation and cryoballoon ablation a predictor of efficacy? Journal of Cardiovascular Medicine, 19(8), 446-452. https://doi.org/10.2459/JCM.0000000000000688